Covid-19,Plasmapheresis. Coronavirus infection, unspecified
Conditions
Interventions
Intervention 1: The intervention group: The COVID-19 patients who will receive Centrifugation plasmapheres which are replaced by FFP. The Plasmapheresis , Lab tests and clinical examinations will be d
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age over 18 years No pregnancy Do not get diseases that require a special treatment protocol Patient with cytokine storm Life-threatening illnesses such as respiratory failure, septic shock, dysfunction or multiple organ failure early ARDS
Exclusion criteria
Exclusion criteria: Age under 18 years pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The prevalence of mortality/morbidity. Timepoint: Three plasmapheres with one or two days apart, examinations and tests in both groups every other day for two weeks and then every week for two weeks. Method of measurement: Patients' lab and file records. | — |
Secondary
| Measure | Time frame |
|---|---|
| Determining the trend of O2 sat level changes in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: pulse oximetre.;Determining the trend of LDH level changes in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: Laboratory test.;Determining the trend of changes in ESR level in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: Laboratory test.;Determining the trend of changes in CRP level in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: Laboratory test.;Determining the trend of changes in ferritin level in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: Laboratory test.;Determining the trend of changes in D-Dimer level in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: ELISA.;Determining the trend of mortality rate changes in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: patient file report.;Determining the mean length of hospital stay in patients treated with plasmapheresis compared with the control group. Timepoint: daily. Method of measurement: Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Nasri
Esfahan University of Medical Sciences
Outcome results
None listed